04 October 2023
04 October 2023
Two lead programmes of POINT, PNT2002 and PNT2003, are currently at the late developmental stage.
SAGE has recommended the vaccine for children aged between six and 16 years.
Following the release of new vaccine batches by the US Center for Biologics Evaluation and Research, the vaccine will be made available across the US in early October 2023.
FDA issues third complete response letter this year for lebrikizumab, citing inspection findings at third-party manufacturer.
The companies will develop additional in vivo CRISPR-based gene editing therapies to treat neurological and muscular diseases.
The company has reached a settlement over safety issues with two heartburn drugs in two US district courts, with a third set for trial next year.
Roche and Novartis’ Xolair (omalizumab) has been approved for treating allergic asthma and multiple food allergies.
The accelerated approval by the FDA was pulled after an Exkivity (mobocertinib) Phase III confirmatory trial failed to meet its primary endpoint.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
